VivoSim Labs, INC. VIVS

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

VivoSim Labs, Inc. ("VivoSim," "we," "us," "our," the "Company" and "our Company"), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies ("NAM") models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.

Last close 0.15 2026-10-23
Market cap $2.2M 2026-06-30 share count
52-week range 0.14 - 3.40

Valuation FY2025 figures against the last close

P/S16.8x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-5.35

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $131.0K$144.0K$109.0K$370.0K$1.5M$0$2.2M$3.1M$4.6M$4.2M
Cost of revenue $0$5.0K———$0$300.0K$500.0K$1.0M$956.0K
Gross profit $131.0K$139.0K———$0$1.9M$2.6M$3.6M$3.3M
R&D $4.2M$5.0M$5.5M$8.9M$3.3M$1.1M$5.3M$14.8M$18.0M$19.5M
SG&A $7.4M$7.7M$9.7M$9.2M$9.7M$15.7M$18.1M$15.1M$20.9M$22.3M
Total operating expenses $11.6M$12.8M$15.2M$18.1M$13.0M$16.8M$23.7M$30.4M$39.9M$42.8M
Operating income -$11.5M-$12.6M-$15.1M-$17.7M-$11.5M-$16.8M-$21.5M-$27.3M-$35.3M-$38.6M
Interest expense $12.0K$10.0K———————$0
Pre-tax income -$13.8M-$2.5M-$14.7M-$17.3M-$11.4M-$16.8M-$18.7M-$26.6M-$34.8M-$38.4M
Income tax $2.0K$2.0K$2.0K$2.0K$2.0K$2.0K$2.0K$3.0K$2.0K$23.0K
Net income -$13.8M-$2.5M-$14.7M-$17.3M-$11.4M-$16.8M-$18.7M-$26.6M-$34.8M-$38.4M
EPS, basic -5.35-1.70-19.25-1.98-1.32—————
EPS, diluted -5.35-1.70-19.25-1.98-1.32-2.44-2.80-0.23-0.32-0.39
Shares, diluted (wtd. avg.) 2.6M1.5M762,0768.7M8.7M—————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $5.0M$11.3M$2.9M$15.3M$28.7M$37.4M$27.4M$36.5M$43.7M$62.8M
Receivables $32.0K$30.0K$33.0K$152.0K$0$0$111.0K$503.0K$883.0K$647.0K
Inventory —$0$297.0K$0——$0$490.0K$842.0K$550.0K
Total current assets $6.6M$12.1M$3.9M$17.0M$29.5M$38.4M$28.3M$38.6M$46.8M$65.1M
Property, plant and equipment $206.0K$419.0K$669.0K$902.0K$662.0K$381.0K$0$1.8M$2.8M$3.8M
Total assets $7.4M$14.7M$6.3M$20.3M$33.3M$39.9M$28.4M$40.6M$49.8M$69.2M
Accounts payable $1.0M$1.6M$627.0K$331.0K$415.0K$281.0K$720.0K$628.0K$464.0K$1.2M
Total current liabilities $2.8M$3.7M$1.9M$3.7M$1.4M$721.0K$1.8M$3.7M$4.7M$6.0M
Total liabilities $8.5M$4.2M$2.7M$5.0M$3.1M$721.0K$1.8M$4.3M$5.2M$6.8M
Retained earnings -$356.0M-$342.2M-$339.7M-$325.0M-$307.7M-$296.3M-$279.5M-$260.8M-$234.1M-$199.3M
Total equity -$1.1M$10.5M$3.6M$15.3M$30.2M$39.2M$26.6M$36.3M$44.6M$62.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$10.8M-$9.5M-$14.7M-$12.4M-$8.5M-$13.3M-$14.9M-$20.4M-$28.9M-$29.2M
Depreciation and amortisation $215.0K$266.0K$280.0K$293.0K$142.0K$41.0K$1.1M$980.0K$1.3M$1.1M
Stock-based compensation ————————$6.9M$7.4M
Capital expenditure $0$13.0K$42.0K$396.0K$409.0K$405.0K$0$79.0K$226.0K$1.4M
Investing cash flow $94.0K$9.0M$816.0K-$966.0K-$409.0K-$393.0K$747.0K-$76.0K-$292.0K-$1.4M
Financing cash flow $4.4M$8.8M$1.4M$0$205.0K$23.8M$4.9M$13.2M$10.1M$31.2M
Buybacks ————$0$1.0K$0———

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-361066.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -40M -20M 0 20M Revenue, FY2016: 4.2M Gross profit, FY2016: 3.3M Net income, FY2016: -38.4M Revenue, FY2017: 4.6M Gross profit, FY2017: 3.6M Net income, FY2017: -34.8M Revenue, FY2018: 3.1M Gross profit, FY2018: 2.6M Net income, FY2018: -26.6M Revenue, FY2019: 2.2M Gross profit, FY2019: 1.9M Net income, FY2019: -18.7M Revenue, FY2020: 0 Gross profit, FY2020: 0 Net income, FY2020: -16.8M Revenue, FY2021: 1.5M Net income, FY2021: -11.4M Revenue, FY2022: 370K Net income, FY2022: -17.3M Revenue, FY2023: 109K Net income, FY2023: -14.7M Revenue, FY2024: 144K Gross profit, FY2024: 139K Net income, FY2024: -2.5M Revenue, FY2025: 131K Gross profit, FY2025: 131K Net income, FY2025: -13.8M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $4.2M $4.6M $3.1M $2.2M $0 $1.5M $370.0K $109.0K $144.0K $131.0K
Gross profit $3.3M $3.6M $2.6M $1.9M $0 — — — $139.0K $131.0K
Net income -$38.4M -$34.8M -$26.6M -$18.7M -$16.8M -$11.4M -$17.3M -$14.7M -$2.5M -$13.8M

Recent filings and events

  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Director nominations Dates and mechanics for shareholders proposing directors. Item 5.08
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Delisting notice Item 3.01
  • Other event Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Material agreement signed Item 1.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%